University of Illinois at Chicago
Exemption #JDR300
Announcement of an Exempt Purchase
Award Info Published Wednesday September 25, 2024
Cardinal Health Specialty Pharmaceutical ServicesColumbia, MD
- Amount: An estimated $7,000,000
- Terms: An estimated start date of 10/1/2024 through 9/30/2027
- Renewals: None
Summary
Vendors
1 total
0 BEP vendors
0 VBP vendors
0 Small businesses
The University award process may be delayed as this award goes through a state approval process.
First published Wednesday, September 25, 2024
The University awarded a contract for Yescarta and Tecartus.
Purchase of specialty pharmaceuticals used in CAR-T (Chimeric Antigen Receptor Therapy), an immunological treatment that uses the bodys own immune system to destroy cancerous cells. These pharmaceuticals (Yescarta and Tecartus) are used as a last option for patients who have failed previous cancer treatment. CAR-T is similar to autologous bone marrow transplant. The patients own white blood cells are harvested, then used to engineer and grow the cell product which is shipped back to UI Hospital to be infused to the patient in the bone marrow transplant unit.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) The manufacturer of Yescarta and Tecartus has licensed the exclusive distribution rights to Cardinal Health Specialty Pharmacy. These products can only be obtained through Cardinal
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire qualified veterans, minorities, females, persons with disabilities and ex-offenders.